Emerging antiplatelet agents, differential pharmacology, and clinical utility. - Wikidata - wikimedia - TriplyDB

Emerging antiplatelet agents, differential pharmacology, and clinical utility.

Emerging antiplatelet agents, differential pharmacology, and clinical utility.

http://www.wikidata.org/entity/Q37979178

about

Pharmacokinetics and tissue distribution study of novel potent antiplatelet agent S007-867 in mice using HPLC-MS/MS.Ticagrelor: An emerging oral antiplatelet agent.Ticagrelor in modern cardiology - an up-to-date review of most important aspects of ticagrelor pharmacotherapy.

P2860

Q39022115-465E3310-E046-4F1F-A267-8149F08BBBFA Q40359329-ED07DBBE-9F83-4F4F-AE45-7252CB9E1584 Q48344587-1BB0015A-3899-4C63-9526-AECA16498810

P2860

Emerging antiplatelet agents, differential pharmacology, and clinical utility.

http://www.wikidata.org/entity/Q37979178

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Emerging antiplatelet agents, differential pharmacology, and clinical utility.

@en

Emerging antiplatelet agents, differential pharmacology, and clinical utility.

@nl

type

label

Emerging antiplatelet agents, differential pharmacology, and clinical utility.

@en

Emerging antiplatelet agents, differential pharmacology, and clinical utility.

@nl

prefLabel

Emerging antiplatelet agents, differential pharmacology, and clinical utility.

@en

Emerging antiplatelet agents, differential pharmacology, and clinical utility.

@nl

P1433

Q37979178-0D3ED9C8-1994-46FA-84DE-D8D9A147444B

P1476

Q37979178-258711E0-13B0-417A-958C-C1B643CA080C

P2093

Q37979178-03B3C086-41A7-48CC-8187-8C9FB74BA0CC

Q37979178-6FB883E6-D9BF-4DBD-8EB7-1C7F35154866

Q37979178-AE2010E6-E8D3-474D-878D-EBC779E33078

Q37979178-C9C09E9E-36F6-4684-9FF0-B7E91ED0C815

P2860

Q37979178-0E88FCFB-DA65-4641-9660-25F281CC1DAB

Q37979178-179B9055-2EE3-46BF-A5F9-0736C6D06263

Q37979178-18F078C2-FED6-4FFB-9AB3-D424DD376E3C

Q37979178-19BBCCFC-E2E6-45FD-873A-591BD649C47F

Q37979178-1F81B0D5-DCFB-466C-8C33-228D977306B8

Q37979178-2015424F-F73B-459D-8692-3AA9C006DA4E

Q37979178-213128D0-E36A-46D9-BF07-F225ED3F0430

Q37979178-29FCEFC5-097F-49D2-899F-3C4B5925CA37

Q37979178-2A7FC768-5A0C-46EC-8D6D-DBEE35931313

Q37979178-2F369F5B-3E35-48AB-921B-4C4EE59A094E

P304

Q37979178-C38A5CE8-4748-453A-B804-7D5BED0CAE15

P31

Q37979178-A1475101-BD80-458F-B375-E9582D18D41A

P356

Q37979178-F6A315A7-B68E-4504-9FF3-353696CFD900

P478

Q37979178-7BAEFADF-1565-4172-8DDF-E01D01EF691E

P577

Q37979178-BC593B75-EA21-4E77-861F-F20BF8B5B31E

P5875

Q37979178-B2EEE075-BC89-42DE-8A1C-E2EEF3BEE595

P698

Q37979178-D9AB73FC-37B8-4F89-8EDA-B91B931A0CDF

P921

Q37979178-9DE10ADF-2C1F-4B34-A76B-6B605011FDB8

P932

Q37979178-EC46BD92-12B6-4D6D-803B-E51221E110E8

P356

P1433

Journal of Blood Medicine

P1476

Emerging antiplatelet agents, differential pharmacology, and clinical utility.

@en

P2093

Carrie S Oliphant

http://www.w3.org/2001/XMLSchema#string

Elizabeth Beach

http://www.w3.org/2001/XMLSchema#string

Pranab Das

http://www.w3.org/2001/XMLSchema#string

Rashmi Thapa

http://www.w3.org/2001/XMLSchema#string

P2860

Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study

Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial

Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes

Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation

Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study

Coronary stent restenosis in patients treated with cilostazol

Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial

Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial

Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin

Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial

P304

79-91

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/JBM.S6596

http://www.w3.org/2001/XMLSchema#string

P478

1

http://www.w3.org/2001/XMLSchema#string

P577

2010-05-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221782424

http://www.w3.org/2001/XMLSchema#string

P698

22282687

http://www.w3.org/2001/XMLSchema#string

P921

P932

3262324

http://www.w3.org/2001/XMLSchema#string